The program will focus on the treatment of autoimmune diseases and will utilize the patient's own adipose-derived mesenchymal stem cells. The stem cells, administered via intravenous infusion, release substances that suppress inflammation and may reduce the need for conventional immunosuppressive drugs and steroids. This will allow us to establish a more efficient treatment with fewer side effects.